GCG

A class action lawsuit is currently pending that includes direct purchasers of branded Zymar or Zymaxid on or between June 15, 2010 and December 31, 2017. A proposed Settlement has been reached between Plaintiff Hartig Drug Company Inc. ("Hartig"), on its own behalf and on behalf of members of the proposed Settlement Class, and the following Defendants: (1) Senju Pharmaceutical Co. Ltd. ("Senju"); (2) Kyorin Pharmaceutical Co., Ltd. ("Kyorin"); and (3) Allergan, Inc. ("Allergan")... Direct purchaser Plaintiff Hartig ("Plaintiff") claims that Defendants engaged in an unlawful scheme to exclude or delay generic competition for gatifloxacin ophthalmic solution (generic versions of their branded drugs Zymar and Zymaxid), a drug approved to treat eye infections such as bacterial conjunctivitis, in violation of the Sherman Act. The Defendants deny any liability as to Plaintiff's claims... A Settlement has now been reached with the Defendants. Approval of this Settlement by the Court will..

Primary location: Dublin United States